View Older Stories View More Recent Stories

Sep 3, 2020 07:30AM Zai Lab Announces Clinical Data to be Presented at ESMO Virtual Congress 2020
Sep 1, 2020 04:05PM Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Aug 31, 2020 07:30AM Zai Lab Announces Upcoming Participation in September Conferences
Aug 31, 2020 07:30AM Zai Lab Announces Upcoming Participation in September Conferences
Aug 17, 2020 04:30PM Deciphera Pharmaceuticals (DCPH) Announces Publication of QINLOCK Phase 1 Study Results in Patients with Gastrointestinal Stromal Tumor in Journal of Clinical Oncology
Aug 17, 2020 04:30PM Deciphera Announces Publication of QINLOCK™ (ripretinib) Phase 1 Study Results in Patients with Gastrointestinal Stromal Tumor in Journal of Clinical Oncology
Aug 17, 2020 07:30AM Zai Lab Appoints F. Ty Edmondson as Chief Legal Officer
Aug 17, 2020 07:30AM Zai Lab Appoints F. Ty Edmondson as Chief Legal Officer
Aug 13, 2020 07:30AM Zai Lab Announces Financial Results for Six Months Ended June 30, 2020 and Corporate Updates
Aug 13, 2020 07:30AM Zai Lab Announces Financial Results for Six Months Ended June 30, 2020 and Corporate Updates
Aug 5, 2020 04:01PM Paratek Pharmaceuticals to Present at Two August 2020 Healthcare Conferences
Aug 4, 2020 04:05PM Deciphera Pharmaceuticals, Inc. Announces Second Quarter 2020 Financial Results
Aug 4, 2020 07:32AM Zai Lab Limited (ZLAB) NDA for Ripretinib Granted Priority Review by China's NMPA
Aug 4, 2020 07:30AM Zai Lab Announces NDA for Ripretinib Granted Priority Review by China’s NMPA
Aug 4, 2020 07:30AM Zai Lab Announces NDA for Ripretinib Granted Priority Review by China’s NMPA
Aug 3, 2020 04:05PM Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Jul 30, 2020 07:30AM Zai Lab to Announce Financial Results for the Six Months Ended June 30, 2020 and Corporate Updates
Jul 30, 2020 07:30AM Zai Lab to Announce Financial Results for the Six Months Ended June 30, 2020 and Corporate Updates
Jul 20, 2020 07:34AM Zai Lab (ZLAB), Deciphera Pharmaceuticals (DCPH) Announce China NMPA Accepts NDA Submission of Ripretinib for Advanced Gastrointestinal Stromal Tumor
Jul 20, 2020 07:30AM China NMPA Accepts NDA Submission of Ripretinib for Advanced Gastrointestinal Stromal Tumor
Jul 20, 2020 07:30AM China NMPA Accepts NDA Submission of Ripretinib for Advanced Gastrointestinal Stromal Tumor
Jul 7, 2020 07:35AM Turning Point Therapeutics Inc. (TPTX), Zai Lab (ZLAB) Announce Exclusive License Agreement for Repotrectinib in Greater China
Jul 7, 2020 07:30AM Turning Point Therapeutics and Zai Lab Announce Exclusive License Agreement For Repotrectinib in Greater China
Jul 7, 2020 07:30AM Turning Point Therapeutics and Zai Lab Announce Exclusive License Agreement for Repotrectinib in Greater China
Jul 7, 2020 07:30AM Turning Point Therapeutics and Zai Lab Announce Exclusive License Agreement for Repotrectinib in Greater China
Jul 7, 2020 07:30AM Turning Point Therapeutics and Zai Lab Announce Exclusive License Agreement For Repotrectinib in Greater China
May 28, 2020 07:38AM Zai Lab Limited (ZLAB) Reports Positive Topline Results from the NORA Phase 3 Study of ZEJULA as Maintenance Therapy
May 28, 2020 07:37AM Zai Lab Announces Positive Topline Results from the NORA Phase 3 Study of ZEJULA® as Maintenance Therapy for Chinese Patients with Platinum-sensitive, Recurrent Ovarian Cancer
May 28, 2020 07:37AM Zai Lab Announces Positive Topline Results from the NORA Phase 3 Study of ZEJULA® as Maintenance Therapy for Chinese Patients with Platinum-sensitive, Recurrent Ovarian Cancer
May 27, 2020 07:30AM Zai Lab Announces Presentations at June Conferences
May 27, 2020 07:30AM Zai Lab Announces Presentations at June Conferences
May 18, 2020 07:32AM Zai Lab Limited (ZLAB) Reports First Chinese Patient Dosed in Global Phase 3 ATTACK Trial of Sulbactam-Durlobactam for Patients with Carbapenem-Resistant Acinetobacter Infections
May 18, 2020 07:30AM Zai Lab Announces First Chinese Patient Dosed in the Global Phase 3 ATTACK Trial of Sulbactam-Durlobactam for Patients with Carbapenem-Resistant Acinetobacter Infections
May 18, 2020 07:30AM Zai Lab Announces First Chinese Patient Dosed in the Global Phase 3 ATTACK Trial of Sulbactam-Durlobactam for Patients with Carbapenem-Resistant Acinetobacter Infections
May 13, 2020 10:10AM China NMPA Approves Optune® for the Treatment of Newly Diagnosed and Recurrent Glioblastoma
May 13, 2020 09:40AM Zai Lab (ZLAB), Novocure (NVCR) Announce China NMPA Approves Optune for Treatment of Newly Diagnosed and Recurrent Glioblastoma
May 13, 2020 09:39AM China NMPA Approves Optune® for the Treatment of Newly Diagnosed and Recurrent Glioblastoma
May 13, 2020 09:39AM China NMPA Approves Optune® for the Treatment of Newly Diagnosed and Recurrent Glioblastoma
May 11, 2020 06:30AM Paratek Pharmaceuticals Announces First Quarter 2020 Total Revenues of $7.9 Million including NUZYRA® (omadacycline) Net Sales of $7.3 Million
May 5, 2020 06:30AM Regeneron Reports First Quarter 2020 Financial and Operating Results
Apr 8, 2020 06:04AM Regeneron (REGN), Zai Lab Report Regional Strategic Collaboration for REGN1979 (CD20xCD3 Bispecific Antibody)
Apr 8, 2020 06:00AM Regeneron and Zai Lab Announce Regional Strategic Collaboration for REGN1979 (CD20xCD3 Bispecific Antibody)
Apr 8, 2020 06:00AM Regeneron and Zai Lab Announce Regional Strategic Collaboration for REGN1979 (CD20xCD3 Bispecific Antibody)
Apr 8, 2020 06:00AM Regeneron and Zai Lab Announce Regional Strategic Collaboration for REGN1979 (CD20xCD3 Bispecific Antibody)
Feb 27, 2020 04:05PM Five Prime Therapeutics Reports Fourth Quarter and Full Year 2019 Results
Feb 25, 2020 04:01PM Paratek Pharmaceuticals Announces Full Year 2019 Total Revenues of $16.5 Million including NUZYRA® (omadacycline) Net Sales of $11.5 Million
Jan 9, 2020 07:32AM Zai Lab Limited (ZLAB), Novocure (NVCR) Report First Patient Enrolled in Ph. 2 Pilot Trial of Tumor Treating Fields with Chemotherapy
Jan 9, 2020 07:30AM Zai Lab and Novocure Announce First Patient Enrolled in a Phase 2 Pilot Trial of Tumor Treating Fields Together with Chemotherapy as First-Line Treatment of Gastric Cancer
Jan 9, 2020 07:30AM Zai Lab and Novocure Announce First Patient Enrolled in a Phase 2 Pilot Trial of Tumor Treating Fields Together with Chemotherapy as First-Line Treatment of Gastric Cancer
Jan 9, 2020 07:30AM Zai Lab and Novocure Announce First Patient Enrolled in a Phase 2 Pilot Trial of Tumor Treating Fields Together with Chemotherapy as First-Line Treatment of Gastric Cancer
View More Recent Stories View Older Stories